Chicago: Global private equity firm GTCR has officially completed its acquisition of Zentiva, marking a significant milestone as it enters a new phase of expansion and innovation in the European generics pharmaceutical market.
The acquisition of Zentiva from Advent positions Zentiva to accelerate its growth trajectory, leveraging GTCR’s extensive experience in healthcare investments and long-term value creation.
The move underscores GTCR’s strategic commitment to scaling Zentiva’s operations and enhancing access to affordable medicines across global markets.
Zentiva, a leading European generics pharmaceutical company, focuses on the development, manufacturing, and supply of generic, branded specialty, and over-the-counter medicines.
Zentiva currently serves more than 100 million people across over 40 countries, supported by robust R&D capabilities and a strong commitment to clinical excellence and product quality.
Under the new ownership, Zentiva will continue to be led by Chief Executive Officer Steffen Saltofte and Executive Chairperson Kieran Murphy. GTCR has longstanding professional relationships with both leaders, who bring extensive experience from their tenures at companies such as Acino and GE HealthCare.
GTCR, which has invested in healthcare for over 45 years, plans to support Zentiva’s next phase of growth through continued investment in new product development, expansion of its portfolio, and broader geographic reach. The strategy aims to enhance patient access to essential medicines while supporting sustainable healthcare systems globally.
Also Read: Infosys Announces Acquisition of Optimum Healthcare IT
Zentiva Serving More Than 100 Million People Across Over 40 Countries
“We are proud of our strong history and footprint. We look forward to partnering with GTCR at an important inflection point following several years of growth,” said Steffen Saltofte, CEO of Zentiva.
“With GTCR’s support and significant industry expertise, we believe we are ideally placed to accelerate our momentum and continue our mission of expanding access to high-quality, affordable medicines to millions of people across Europe.”
Echoing this sentiment, Sean Cunningham, Managing Director and Head of Healthcare at GTCR, stated, “We are excited to partner with Steffen and team to further the Company’s success. As policymakers increasingly prioritize expanding access to essential medicines while ensuring long-term sustainability of healthcare systems, Zentiva plays a critical role in delivering high-quality, cost-effective therapies at scale. Combined with its differentiated geographic footprint and low-cost manufacturing capabilities, the company is well positioned to strengthen its competitive advantage and deliver long-term growth and impact.”
Also Read: Capgemini Announces Acquisition of Piterion to Expand Global PLM and MOM Expertise
Tom Allen, Managing Director at Advent, added, “We are immensely proud of the business Zentiva has become during our partnership – a scaled, growing European generics platform, with a strong competitive footprint, a commitment to quality, and a clear mission to expand access to affordable medicines.
We would like to thank Steffen and all the talented team members who played a part in the company’s transformation. We look forward to watching Zentiva go from strength to strength in the years ahead.”
As part of the transaction, GTCR was advised by Barclays Bank PLC, BNP Paribas, and Morgan Stanley & Co. LLC on financial matters, with legal counsel provided by Kirkland & Ellis LLP.
Advent was advised by Goldman Sachs and PJT Partners as lead financial advisors, with legal advisory from Freshfields.
